{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T14:38:48Z","timestamp":1770993528783,"version":"3.50.1"},"reference-count":29,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"33","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American Society of Clinical Oncology Educational Book"],"published-print":{"date-parts":[[2013,5]]},"abstract":"<jats:p> Recent studies have suggested that pediatric-intensive chemotherapy regimens can improve outcomes in adults with acute lymphoblastic leukemia (ALL) up to the age of 45. Above this age, toxicities increase. Monoclonal antibody-based therapies bring the promise of increased response rates without excessive toxicity. The addition of rituximab to combination chemotherapy has shown encouraging results. Newer monoclonal antibody-based therapies linked to cytotoxic agents show promise. These include inotuzumab ozogamicin, an anti-CD22 antibody linked to calicheamicin that has produced significant single-agent responses in relapsed and refractory ALL. Other monoclonal antibodies linked to plant or bacterial toxins are in earlier stages of development. Blinatumomab is a novel bispecific T-cell engaging antibody that combines single chain antibodies to CD19 and CD3 and brings a T cell in close proximity to a leukemic lymphoblast with resulting redirected lysis. This agent has demonstrated encouraging results in both the minimal residual disease setting and the relapsed\/refractory setting. Autologous chimeric antigen receptor cells have shown promising responses in indolent B-cell lymphoid malignancies and are being tested in ALL. Many of these agents have the potential to increase response rates in older adults. Trials of many of these monoclonal antibody-based therapies are in various stages of development in the treatment of newly diagnosed ALL. <\/jats:p>","DOI":"10.14694\/edbook_am.2013.33.294","type":"journal-article","created":{"date-parts":[[2020,2,7]],"date-time":"2020-02-07T18:55:36Z","timestamp":1581101736000},"page":"294-299","source":"Crossref","is-referenced-by-count":24,"title":["Monoclonal Antibody-Based Therapies in the Treatment of Acute Lymphoblastic Leukemia"],"prefix":"10.1200","author":[{"given":"Mark R.","family":"Litzow","sequence":"first","affiliation":[{"name":"From the Division of Hematology, Mayo Clinic, Rochester, MN."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"233","reference":[{"key":"bibr1-EdBookAM201333294","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-01-130237"},{"key":"bibr2-EdBookAM201333294","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.18.6916"},{"key":"bibr3-EdBookAM201333294","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.41.6768"},{"key":"bibr4-EdBookAM201333294","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-06-164129"},{"key":"bibr5-EdBookAM201333294","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.9456"},{"key":"bibr6-EdBookAM201333294","first-page":"170","volume":"116","author":"Hoelzer D","year":"2010","journal-title":"ASH Annual Meeting Abstracts."},{"key":"bibr7-EdBookAM201333294","first-page":"3982S","volume":"9","author":"Carnahan J","year":"2003","journal-title":"Clin Cancer Res."},{"key":"bibr8-EdBookAM201333294","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.01.082"},{"key":"bibr9-EdBookAM201333294","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.3528"},{"key":"bibr10-EdBookAM201333294","first-page":"573","volume":"118","author":"Raetz EA","year":"2011","journal-title":"ASH Annual Meeting Abstracts."},{"key":"bibr11-EdBookAM201333294","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1182\/blood.V120.21.2603.2603","volume":"120","author":"Advani A","year":"2012","journal-title":"Blood."},{"key":"bibr12-EdBookAM201333294","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2010.08387.x"},{"key":"bibr13-EdBookAM201333294","doi-asserted-by":"publisher","DOI":"10.2174\/1381612003398564"},{"key":"bibr14-EdBookAM201333294","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.1900"},{"key":"bibr15-EdBookAM201333294","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70386-2"},{"key":"bibr16-EdBookAM201333294","first-page":"671","volume":"120","author":"O'Brien S","year":"2012","journal-title":"ASH Annual Meeting Abstracts."},{"key":"bibr17-EdBookAM201333294","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2012.07.013"},{"key":"bibr18-EdBookAM201333294","volume-title":"11th International Conference on Malignant Lymphoma.","author":"Goebeler M","year":"2011"},{"key":"bibr19-EdBookAM201333294","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-07-441030"},{"key":"bibr20-EdBookAM201333294","first-page":"670","volume":"120","author":"Topp MS","year":"2012","journal-title":"ASH Annual Meeting Abstracts."},{"key":"bibr21-EdBookAM201333294","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-0487"},{"key":"bibr22-EdBookAM201333294","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-2980"},{"key":"bibr23-EdBookAM201333294","first-page":"248","volume":"118","author":"Wayne AS","year":"2011","journal-title":"ASH Annual Meeting Abstracts."},{"key":"bibr24-EdBookAM201333294","doi-asserted-by":"publisher","DOI":"10.1097\/MPH.0b013e3181bdf211"},{"key":"bibr25-EdBookAM201333294","first-page":"277","volume":"9","author":"Park JH","year":"2010","journal-title":"Discov Med."},{"key":"bibr26-EdBookAM201333294","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1016\/j.hoc.2011.09.015","volume":"25","author":"Park JH","year":"2011","journal-title":"Hematol Oncol Clin North Am."},{"key":"bibr27-EdBookAM201333294","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1103849"},{"key":"bibr28-EdBookAM201333294","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-10-384388"},{"key":"bibr29-EdBookAM201333294","author":"Haso W","journal-title":"Blood."}],"container-title":["American Society of Clinical Oncology Educational Book"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.14694\/EdBook_AM.2013.33.294","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,29]],"date-time":"2022-05-29T07:25:08Z","timestamp":1653809108000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.14694\/EdBook_AM.2013.33.294"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5]]},"references-count":29,"aliases":["10.1200\/edbook_am.2013.33.294","10.1200\/edbook_am.2013.33.294"],"journal-issue":{"issue":"33","published-print":{"date-parts":[[2013,5]]}},"alternative-id":["10.14694\/EdBook_AM.2013.33.294"],"URL":"https:\/\/doi.org\/10.14694\/edbook_am.2013.33.294","relation":{},"ISSN":["1548-8748","1548-8756"],"issn-type":[{"value":"1548-8748","type":"print"},{"value":"1548-8756","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,5]]}}}